Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
about
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancerUrate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancerRasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in goutRisk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) projectRecognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignanciesRasburicase in the management of tumor lysis: an evidence-based review of its place in therapyTumor lysis syndrome: new challenges and recent advances.Oral uricase eliminates blood uric acid in the hyperuricemic pig model.A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experienceThe optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome.Clarifying the role of rasburicase in tumor lysis syndrome.Management of tumor lysis syndrome in adults.One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.Rasburicase for the treatment of tumor lysis in hematological malignancies.Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer.Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight Patients.Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
P2860
Q24194387-FE0827C0-AE37-41B7-A822-14F8B9810F24Q24234902-B538E71E-0689-45A8-92F2-93AB674FA7ADQ24673444-F72B4B7E-E2F8-4E7A-BA5F-9D9F1DEB5B83Q26822723-53C6097A-D631-4FFE-9B15-E9260AE9A0B7Q26862904-83DE9F93-6D97-4D75-A4DD-DC441442096DQ28082089-79E3580E-4478-449A-BCBF-D9C438DDDB75Q33595615-83FA3315-B768-4227-A758-FA2A8836272BQ33778745-C80A496C-A8B3-4326-B562-76F1E8A40314Q33947841-ABFBBE14-061E-469F-9A20-F16388674D6DQ35683889-A53594E1-482F-4643-88D7-929FB4F64810Q35742173-5C3A28C3-36D9-41D3-8E8A-2D4DE9B4A3EAQ36204470-264E5732-41F1-4F1C-8E8F-1D39274A982BQ36629257-83670720-9E32-4DEE-AD09-947D91EB1208Q36693863-C31BAE16-0B2B-4B23-B713-A10A1C963720Q36731440-ED7D1DAE-7AD5-47C0-A1B5-E5DD9DC28855Q37372898-E1D14F60-CF2D-4534-A5CB-AF8DD75B2D9AQ37586944-47AD2C89-0B4C-465F-B959-A71E1167E7B0Q37634744-E3374550-9FDC-44A7-AF00-BD9EE21FD4B3Q37717853-C7FC503B-EC7B-47AF-924B-39F1F134951FQ37788882-854D3467-0541-4613-937C-18854D91924EQ37978342-838ECD40-8A33-4007-A5DF-D3579823DABAQ38086143-B6C252E0-819A-418D-BF3F-6881765366FBQ38189226-960280BD-D016-45BB-BD81-E0650517C9F7Q38921102-12BA370C-967C-4043-84CD-FBA79909F6B7Q40065094-9E01C6A3-BE35-4370-8BC8-EBE74DB01765Q46575274-44AEB00E-806E-4952-B1E3-24F0408ECCD8Q46599361-BF5E09B8-4CD5-405E-8820-76E80719DA8FQ46849211-60C7CAFD-5283-4D00-9558-731C16FA8AF8Q47580177-5D31979C-F6CF-4D57-A0C7-22B7010691A4Q48033577-812EF370-9D3F-4135-81A0-91873CED3173Q50102657-7F646A9D-0D3F-4AB6-962C-065B258CCD88Q58767936-0C2F8DAE-0AF7-45A5-809A-C0A1F2EB8707
P2860
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Reduced-dose rasburicase (reco ...... r patients with hyperuricemia.
@ast
Reduced-dose rasburicase (reco ...... r patients with hyperuricemia.
@en
type
label
Reduced-dose rasburicase (reco ...... r patients with hyperuricemia.
@ast
Reduced-dose rasburicase (reco ...... r patients with hyperuricemia.
@en
prefLabel
Reduced-dose rasburicase (reco ...... r patients with hyperuricemia.
@ast
Reduced-dose rasburicase (reco ...... r patients with hyperuricemia.
@en
P2093
P2860
P356
P1476
Reduced-dose rasburicase (reco ...... er patients with hyperuricemia
@en
P2093
S Trifilio
P2860
P2888
P304
P356
10.1038/SJ.BMT.1705379
P407
P577
2006-06-01T00:00:00Z